Massachusetts Financial Services Co. MA raised its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 14.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 535,083 shares of the company’s stock after purchasing an additional 69,227 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.72% of SpringWorks Therapeutics worth $20,157,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of SpringWorks Therapeutics by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 6,529,325 shares of the company’s stock valued at $321,373,000 after buying an additional 492,783 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of SpringWorks Therapeutics by 48.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company’s stock worth $202,318,000 after acquiring an additional 1,333,892 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in shares of SpringWorks Therapeutics during the first quarter worth approximately $114,083,000. Point72 Asset Management L.P. lifted its holdings in shares of SpringWorks Therapeutics by 310.7% in the 4th quarter. Point72 Asset Management L.P. now owns 2,162,176 shares of the company’s stock worth $78,919,000 after acquiring an additional 1,635,722 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its stake in shares of SpringWorks Therapeutics by 28.7% in the 4th quarter. Perceptive Advisors LLC now owns 1,957,246 shares of the company’s stock valued at $71,439,000 after purchasing an additional 436,830 shares in the last quarter.
SpringWorks Therapeutics Trading Down 2.7 %
SWTX stock opened at $34.38 on Friday. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of -6.69 and a beta of 0.79. The firm’s 50-day moving average price is $37.80 and its two-hundred day moving average price is $41.38. SpringWorks Therapeutics, Inc. has a 12-month low of $18.00 and a 12-month high of $53.92.
Analysts Set New Price Targets
Several analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their price target on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. HC Wainwright reissued a “buy” rating and issued a $76.00 target price on shares of SpringWorks Therapeutics in a research note on Wednesday, August 28th. Finally, Wedbush restated an “outperform” rating and set a $77.00 price target (up from $75.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $68.50.
Check Out Our Latest Stock Analysis on SWTX
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Featured Articles
- Five stocks we like better than SpringWorks Therapeutics
- Buy P&G Now, Before It Sets A New All-Time High
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- 3 Healthcare Dividend Stocks to Buy
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- The Risks of Owning Bonds
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding SWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report).
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.